Cytoprotective therapy for kidney injury in patients with ST-elevation myocardial infarction

Author:
N.YU. BOROVKOVA¹, A.S. ILYINA¹, A.A. SPASSKY², N.N. BOROVKOV¹, G.V. KOVALEVA^3
1Federal State Budgetary Educational Establishment of Higher Training «Nizhny Novgorod state medical academy» of the Ministry of Public Health; ²Federal State Budgetary Educational Establishment of Higher Training «The Pirogov Russian National Research Medical University» of the Ministry of Public Health; ³State Budgetary Institution of Health Nizhny Novgorod region «Nizhny Novgorod Regional Clinical Hospital named after NA Semashko»

Summary:
Aim. To study an effectiveness of mexidol (ethylmethylhydroxypyridine succinate) for kidney injury in patients with ST-elevation myocardial infarction (STEMI). Material and methods. The study involved 55 STEMI patients. Acute renal injury (ARI) was determined according to basal creatinine, serum creatinine, glomerular filtration rate, cystatin C and NGAL. In STEMI patients standard therapy was supplemented by antioxidant (cytoprotector) mexidol from the 1st to the 10th day 750 mg/day intravenously. ARI values were assessed after treatment. Results. There were 36 ARI patients among 55 patients with STEMI. Therapy with mexidol significantly decreased ARI severity (urine creatinine, cystatin C and NGAL values) after 48 hours. Conclusion. Mexidol may be used in addition to standard therapy in STEMI patients to reduce ARI severity.

Keywords: cytoprotectors, myocardial infarction, acute renal injury.